Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CN1201389) Method and pharmaceutical composition for regulating lipid concentration

Office : China
Application Number: 96198010.9 Application Date: 02.10.1996
Publication Number: 1201389 Publication Date: 09.12.1998
Grant Number: 1217656 Grant Date: 07.09.2005
Publication Kind : C
Prior PCT appl.: Application Number:PCTUS1996015854 ; Publication Number:1997016184 Click to see the data
IPC:
A61K 31/40
A61K 31/18
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
18
Sulfonamides
CPC:
A61K 31/40
A61K 31/165
A61K 31/17
A61K 31/215
A61K 31/22
A61K 31/255
A61K 31/325
A61K 31/365
A61K 31/405
A61K 31/41
A61K 31/44
A61K 45/06
Y02A 50/406
Y10S 514/824
Applicants: Warner-Lambert Co.
沃尼尔·朗伯公司
Inventors: T. M. A. Bocan
T·M·A·博坎
Agents: li huayang
中国国际贸易促进委员会专利商标事务所
Priority Data: 60/006,155 02.11.1995 US
Title: (EN) Method and pharmaceutical composition for regulating lipid concentration
(ZH) 用于调节脂浓度的方法和药物组合物
Abstract:
(EN) The present invention is a combination of an ACAT inhibitor, for example, sulfamic acid, [[2,4,6,-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
(ZH)

本发明涉及ACAT抑制剂,例如氨基磺酸、〔〔2、4、6-三(1-甲基乙基)苯基〕乙酰基〕-、2、6-二(1-甲基乙基)苯基酯、与HMG-CoA还原酶抑制剂,例如阿托伐他汀(atorvastatin),的组合,该组合对脂的调节有效。药剂的组合导致比单独使用两者任一个时更大地降低血浆VLDL和LDL胆固醇并升高HDL胆固醇,导致一种较少致动脉粥样硬化的脂蛋白分布。这种组合用于治疗易于患有或处于产生局部缺血综合症的病人以恢复内源血管内皮依赖性活性。


Also published as:
CZPV1998-1271IS4720NO19981961SK55798KR1020040029459SG53241
IL123902EP0858336US6124309JPH11515025 CN1679953CA2233558
EA199800420KR1019990067270NZ319906NZ512484AU1996072539IN2115/DEL/1996
GEP20001898BWO/1997/016184